Tags

Type your tag names separated by a space and hit enter

[Efficacy evaluation of an oral powder supplement enriched with eicosapentaenoic acid in cancer patients].
Nutr Hosp. 2011 Nov-Dec; 26(6):1385-93.NH

Abstract

BACKGROUND AND OBJECTIVES

The beneficial effect of eicosapentaenoic acid in cancer patients is widely described especially in relation to its role in tumour cachexia. The aim of the study was to evaluate the efficacy of administration of a new oral powder supplement enriched with eicosapentaenoic acid compared to a standard liquid supplement in cancer patients.

PATIENTS AND METHODS

A total of 61 cancer patients, aged more than 18 years, were randomized to receive during a month a bonus of 600 kcal/ day to their regular diet with an oral powder supplement enriched with eicosapentaenoic acid (1.5 g) (RSI) or with a standard liquid supplement (RE). The following data were collected at baseline and after one month: the Patient-Generated Subjective Global Assessment (pg-SGA), anthropometric measurements (skin folds, circumferences and bioimpedance), dietary parameters (3-day food record), biochemical and inflammatory parameters (basic biochemistry, cytokines, prealbumin and Reactive C Protein). Quality of life was evaluated using the SF-36 questionnaire. At the end, scales were used to asses sensory perception, tolerance and satiety induced by the products and motivation to eat.

RESULTS

40 patients completed the study. After intervention, anthropometric parameters do not change and prealbumin values increased significantly in both groups (RSI 16.11 ± 5.66 mg/dl vs. 19.81 ± 6.75 mg/dl p < 0.05 and RE 6.13 ± 16.55 mg/dl vs. 19.03 ± 5.47 mg / dl p < 0.05). RSI group significantly decreased interferon gamma (INF-γ) values (0.99 ± 0.95 vs. 0.65 ± 0.92 pg/ml, p < 0.05). In contrast, RE group increased INF-γ after intervention (1.62 ± 1 27 vs. 2.2 ± 3.19 pg/ml, p < 0.05). There were no significant differences in hunger, appetite, satiety and intake capacity in both groups. The SF-36 scores improved in both groups.

CONCLUSIONS

Supplementation based on an oral powder formula enriched with 1.5 g EPA during one month in cancer patients improved certain inflammatory parameters. This product may be a novel and valuable option to be added to the nutritional intervention strategies used for cancer patients.

Authors+Show Affiliations

Unidad de Nutrición Clínica y Dietética, Hospital Universitario La Paz, IdiPAZ, Madrid, España. carmengomezcandela@telefonica.netNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article
Randomized Controlled Trial

Language

spa

PubMed ID

22411387

Citation

Gómez-Candela, C, et al. "[Efficacy Evaluation of an Oral Powder Supplement Enriched With Eicosapentaenoic Acid in Cancer Patients]." Nutricion Hospitalaria, vol. 26, no. 6, 2011, pp. 1385-93.
Gómez-Candela C, Villarino Sanz M, Horrisberger A, et al. [Efficacy evaluation of an oral powder supplement enriched with eicosapentaenoic acid in cancer patients]. Nutr Hosp. 2011;26(6):1385-93.
Gómez-Candela, C., Villarino Sanz, M., Horrisberger, A., Loria Kohen, V., Bermejo, L. M., & Zamora Auñón, P. (2011). [Efficacy evaluation of an oral powder supplement enriched with eicosapentaenoic acid in cancer patients]. Nutricion Hospitalaria, 26(6), 1385-93. https://doi.org/10.1590/S0212-16112011000600028
Gómez-Candela C, et al. [Efficacy Evaluation of an Oral Powder Supplement Enriched With Eicosapentaenoic Acid in Cancer Patients]. Nutr Hosp. 2011;26(6):1385-93. PubMed PMID: 22411387.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Efficacy evaluation of an oral powder supplement enriched with eicosapentaenoic acid in cancer patients]. AU - Gómez-Candela,C, AU - Villarino Sanz,M, AU - Horrisberger,A, AU - Loria Kohen,V, AU - Bermejo,L M, AU - Zamora Auñón,P, PY - 2011/06/11/received PY - 2011/06/17/accepted PY - 2012/3/14/entrez PY - 2012/3/14/pubmed PY - 2012/7/4/medline SP - 1385 EP - 93 JF - Nutricion hospitalaria JO - Nutr Hosp VL - 26 IS - 6 N2 - BACKGROUND AND OBJECTIVES: The beneficial effect of eicosapentaenoic acid in cancer patients is widely described especially in relation to its role in tumour cachexia. The aim of the study was to evaluate the efficacy of administration of a new oral powder supplement enriched with eicosapentaenoic acid compared to a standard liquid supplement in cancer patients. PATIENTS AND METHODS: A total of 61 cancer patients, aged more than 18 years, were randomized to receive during a month a bonus of 600 kcal/ day to their regular diet with an oral powder supplement enriched with eicosapentaenoic acid (1.5 g) (RSI) or with a standard liquid supplement (RE). The following data were collected at baseline and after one month: the Patient-Generated Subjective Global Assessment (pg-SGA), anthropometric measurements (skin folds, circumferences and bioimpedance), dietary parameters (3-day food record), biochemical and inflammatory parameters (basic biochemistry, cytokines, prealbumin and Reactive C Protein). Quality of life was evaluated using the SF-36 questionnaire. At the end, scales were used to asses sensory perception, tolerance and satiety induced by the products and motivation to eat. RESULTS: 40 patients completed the study. After intervention, anthropometric parameters do not change and prealbumin values increased significantly in both groups (RSI 16.11 ± 5.66 mg/dl vs. 19.81 ± 6.75 mg/dl p < 0.05 and RE 6.13 ± 16.55 mg/dl vs. 19.03 ± 5.47 mg / dl p < 0.05). RSI group significantly decreased interferon gamma (INF-γ) values (0.99 ± 0.95 vs. 0.65 ± 0.92 pg/ml, p < 0.05). In contrast, RE group increased INF-γ after intervention (1.62 ± 1 27 vs. 2.2 ± 3.19 pg/ml, p < 0.05). There were no significant differences in hunger, appetite, satiety and intake capacity in both groups. The SF-36 scores improved in both groups. CONCLUSIONS: Supplementation based on an oral powder formula enriched with 1.5 g EPA during one month in cancer patients improved certain inflammatory parameters. This product may be a novel and valuable option to be added to the nutritional intervention strategies used for cancer patients. SN - 1699-5198 UR - https://www.unboundmedicine.com/medline/citation/22411387/[Efficacy_evaluation_of_an_oral_powder_supplement_enriched_with_eicosapentaenoic_acid_in_cancer_patients]_ L2 - http://www.diseaseinfosearch.org/result/5395 DB - PRIME DP - Unbound Medicine ER -